Log in

NYSE:ZBHZimmer Biomet Stock Price, Forecast & News

$117.64
-1.28 (-1.08 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$115.05
Now: $117.64
$119.35
50-Day Range
$115.43
MA: $124.90
$137.40
52-Week Range
$74.37
Now: $117.64
$161.11
Volume1.55 million shs
Average Volume1.68 million shs
Market Capitalization$24.28 billion
P/E Ratio64.99
Dividend Yield0.82%
Beta1.31
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and office based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Read More
Zimmer Biomet logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.16 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone574-267-6131

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.98 billion
Cash Flow$13.00 per share
Book Value$60.25 per share

Profitability

Net Income$1.13 billion

Miscellaneous

Employees19,900
Market Cap$24.28 billion
Next Earnings Date8/4/2020 (Confirmed)
OptionableOptionable

Receive ZBH News and Ratings via Email

Sign-up to receive the latest news and ratings for ZBH and its competitors with MarketBeat's FREE daily newsletter.

Zimmer Biomet (NYSE:ZBH) Frequently Asked Questions

How has Zimmer Biomet's stock been impacted by COVID-19 (Coronavirus)?

Zimmer Biomet's stock was trading at $111.19 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ZBH shares have increased by 5.8% and is now trading at $117.64. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zimmer Biomet?

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zimmer Biomet in the last year. There are currently 4 hold ratings, 20 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zimmer Biomet.

When is Zimmer Biomet's next earnings date?

Zimmer Biomet is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Zimmer Biomet.

How can I listen to Zimmer Biomet's earnings call?

Zimmer Biomet will be holding an earnings conference call on Tuesday, August 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Zimmer Biomet's earnings last quarter?

Zimmer Biomet Holdings Inc (NYSE:ZBH) issued its quarterly earnings results on Monday, May, 11th. The medical equipment provider reported $1.70 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.53 by $0.17. The medical equipment provider earned $1.78 billion during the quarter, compared to analyst estimates of $1.79 billion. Zimmer Biomet had a return on equity of 13.29% and a net margin of 4.84%. The firm's quarterly revenue was down 9.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.87 earnings per share. View Zimmer Biomet's earnings history.

How often does Zimmer Biomet pay dividends? What is the dividend yield for Zimmer Biomet?

Zimmer Biomet declared a quarterly dividend on Thursday, June 11th. Stockholders of record on Monday, June 29th will be paid a dividend of $0.24 per share on Friday, July 31st. This represents a $0.96 annualized dividend and a dividend yield of 0.82%. The ex-dividend date is Friday, June 26th. View Zimmer Biomet's dividend history.

What price target have analysts set for ZBH?

26 Wall Street analysts have issued 12-month price objectives for Zimmer Biomet's stock. Their forecasts range from $115.00 to $177.00. On average, they anticipate Zimmer Biomet's stock price to reach $146.67 in the next year. This suggests a possible upside of 24.7% from the stock's current price. View analysts' price targets for Zimmer Biomet.

Has Zimmer Biomet been receiving favorable news coverage?

Media stories about ZBH stock have trended somewhat negative on Saturday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Zimmer Biomet earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned media headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news about Zimmer Biomet.

Who are some of Zimmer Biomet's key competitors?

What other stocks do shareholders of Zimmer Biomet own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zimmer Biomet investors own include Walt Disney (DIS), AT&T (T), Cisco Systems (CSCO), Intel (INTC), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and Verizon Communications (VZ).

Who are Zimmer Biomet's key executives?

Zimmer Biomet's management team includes the following people:
  • Mr. Bryan C. Hanson, Pres, CEO & Director (Age 52)
  • Mr. Daniel P. Florin Sr., Exec. VP & CFO (Age 55)
  • Mr. Chad F. Phipps, Sr. VP, Gen. Counsel & Sec. (Age 47)
  • Mr. Sang Yi, Pres of Asia Pacific (Age 57)
  • Mr. Ivan Tornos, Group Pres of Orthopedics (Age 43)

What is Zimmer Biomet's stock symbol?

Zimmer Biomet trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

Who are Zimmer Biomet's major shareholders?

Zimmer Biomet's stock is owned by a number of institutional and retail investors. Top institutional investors include Wedge Capital Management L L P NC (0.33%), Reinhart Partners Inc. (0.06%), Envestnet Asset Management Inc. (0.04%), State of Alaska Department of Revenue (0.03%), Jacobs & Co. CA (0.02%) and Farmers Trust Co. (0.02%). Company insiders that own Zimmer Biomet stock include Arthur J Higgins, Aure Bruneau, Betsy J Bernard, Bryan C Hanson, Chad F Phipps, Didier Deltort, Michael J Farrell, Michael W Michelson, Sang Yi, Syed A Jafry and Tony W Collins. View institutional ownership trends for Zimmer Biomet.

Which institutional investors are selling Zimmer Biomet stock?

ZBH stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, Reinhart Partners Inc., Envestnet Asset Management Inc., Farmers Trust Co., Exane Derivatives, Legacy Capital Partners Inc., Whittier Trust Co., and M&R Capital Management Inc.. Company insiders that have sold Zimmer Biomet company stock in the last year include Aure Bruneau, Chad F Phipps, Didier Deltort, and Sang Yi. View insider buying and selling activity for Zimmer Biomet.

Which institutional investors are buying Zimmer Biomet stock?

ZBH stock was bought by a variety of institutional investors in the last quarter, including TrimTabs Asset Management LLC, State of Alaska Department of Revenue, Canandaigua National Corp, Aries Wealth Management, Independence Bank of Kentucky, DNB Asset Management AS, Norway Savings Bank, and Ellevest Inc.. Company insiders that have bought Zimmer Biomet stock in the last two years include Arthur J Higgins, Betsy J Bernard, Bryan C Hanson, Michael J Farrell, Michael W Michelson, and Syed A Jafry. View insider buying and selling activity for Zimmer Biomet.

How do I buy shares of Zimmer Biomet?

Shares of ZBH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zimmer Biomet's stock price today?

One share of ZBH stock can currently be purchased for approximately $117.64.

How big of a company is Zimmer Biomet?

Zimmer Biomet has a market capitalization of $24.28 billion and generates $7.98 billion in revenue each year. The medical equipment provider earns $1.13 billion in net income (profit) each year or $7.87 on an earnings per share basis. Zimmer Biomet employs 19,900 workers across the globe.

What is Zimmer Biomet's official website?

The official website for Zimmer Biomet is www.zimmerbiomet.com.

How can I contact Zimmer Biomet?

Zimmer Biomet's mailing address is 345 EAST MAIN STREET, WARSAW IN, 46580. The medical equipment provider can be reached via phone at 574-267-6131 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.